The British firm of branded, injectable and generic products for the health sector could come out on top of its current trading range.

The group benefits from solid financial statements. Its Injectable drugs segment increased 15% during the last year and the recent acquisition of US generic injectable drugs business of the German pharmaceutical Boehringer seeks to boost it even more in the future. This strategic acquisition also gives it more visibility in the American market that improved 37% in last fiscal year. Net income is expected to emerge at $226 million, so an increase of 6%. Leverage must fall to 0.4x in 2014, from 0.58x in 2013. EPS revisions moves upward from month to month, thus shareholders could perceive $1.14 per share by the end of the year and $1.21 in 2015.

The stock could continue its course over the GBp 1709 midterm resistance in the future strengthening its bullish trend and drawing unprecedented advances in prices. All time scales moving averages support the positive evolution of the security. However, investors are called to remain cautious and only open buyer’s positions in the case of a breakout over the resistance level. The target price in the short term could be placed at the top line, once these level attained new possibilities could be evaluated. The stop loss will be triggered below the GBp 1623 support, avoiding big losses.